December 29, 2022
FOR IMMEDIATE RELEASE
December 29, 2022
WASHINGTON, DC—The Federal Circuit affirmed a victory for Finnegan on behalf of client BioDelivery Sciences International (BDSI) in a Hatch-Waxman Abbreviated New Drug Application (ANDA) patent infringement case against Alvogen. The case was on appeal from the U.S. District Court for the District of Delaware before Chief Judge Colm Connolly. The case involved Alvogen’s attempt to market generic copies of BDSI’s highly successful Belbuca© buprenorphine buccal film product, a unique opioid that is used to manage severe pain. Belbuca© is BDSI’s backbone product with sales of over $100 million per year.
Following a three-day bench trial in March 2021, Judge Connolly ruled that Alvogen failed to prove by clear and convincing evidence that claims 4 and 5 of U.S. Patent No. 8,147,866 and claims 9 and 20 of U.S. Patent 9,901,539—to which Alvogen stipulated to infringement—were invalid for obviousness or anticipation.
The ruling, which prohibited the sale of Alvogen’s generic buprenorphine buccal film product until after the ’539 patent expires, in 2032, was favorable to BDSI. On appeal, the Federal Circuit affirmed Judge Connolly’s ruling on the ’866 and ’539 patents, thereby preserving this expressive win.
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP is one of the largest IP law firms in the world. From offices in Atlanta, Boston, London, Munich, Palo Alto, Reston, Seoul, Shanghai, Taipei, Tokyo, and Washington, DC, the firm practices all aspects of patent, trademark, and copyright law, including counseling, prosecution, licensing, and litigation. Finnegan also represents clients on IP issues related to advertising, trade secret law, European patents and trade marks, international trade, portfolio management, the Internet, e-commerce, government contracts, antitrust, and unfair competition. For additional information on the firm, please visit www.finnegan.com and follow us on LinkedIn.
Award/Ranking
Managing IP Americas Awards 2024: Finnegan Shortlisted for Nine Awards, Including Firm of the Year
March 12, 2024
Commentary
February 29, 2024
Press Release
Finnegan Secures Another Patent Victory for BMW Group in the District of Delaware
February 27, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.